SCHEMBL3286587

SCHEMBL3286587

Cc1nc(N)cc(N2CCN(C)CC2)n1

nearest known ligand 0.72

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 10/20 0.72
HRH3 Q9Y5N1 1/20 0.72
HTR3A P46098 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5144572 0.85 HRH4 (0.58) HRH4HRH3
SCHEMBL30488018 0.84 HRH4 (1.00) HRH4HRH3
SCHEMBL2169898 0.84 HRH4 (1.00) HRH4HRH3
SCHEMBL10849481 0.82 HRH4 (0.90) HRH4HRH3
SCHEMBL22275729 0.81 HRH4 (0.59) HRH4HRH3HTR3A
SCHEMBL30068075 0.81 HRH4 (0.49) HRH4HRH3
SCHEMBL26647349 0.81 HRH4 (0.49) HRH4HRH3
SCHEMBL793547 0.81 HRH4 (0.51) HRH4HRH3
SCHEMBL30011158 0.81 HRH4 (0.51) HRH4HRH3
SCHEMBL794010 0.81 CRHBP (0.61) HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101796046-A Pyrimidine derivatives 934 ASTRAZENECA AB 2010-08-04 CN disclosed
US-7718653-B2 Pyrimidine derivatives for inhibiting Eph receptors ASTRAZENECA AB (SE) 2010-05-18 US disclosed
EP-2183242-A2 PYRIMIDINE DERIVATIVES 934 AstraZeneca AB (SE) 2010-05-12 EP disclosed
US-20090023719-A1 PYRIMIDINE DERIVATIVES 934 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2009010789-A2 PYRIMIDINE DERIVATIVES 934 ASTRAZENECA AB (SE) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023719-A1 PYRIMIDINE DERIVATIVES 934 EPHB4, EPHA2, EPHB1 HRH4 177/4885HRH3 363/4885HTR3A 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.